Focused On-demand Library for Prokineticin receptor 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NFJ6

UPID:

PKR2_HUMAN

Alternative names:

G-protein coupled receptor 73-like 1; G-protein coupled receptor I5E; GPR73b; GPRg2

Alternative UPACC:

Q8NFJ6; A5JUU1; Q2M3C0; Q5TDY1; Q9NTT0

Background:

Prokineticin receptor 2, known by names such as G-protein coupled receptor 73-like 1 and GPR73b, plays a pivotal role in cellular signaling. It is exclusively coupled to the G(q) subclass of heteromeric G proteins, leading to calcium mobilization, phosphoinositide turnover, and activation of p44/p42 mitogen-activated protein kinase.

Therapeutic significance:

Linked to Hypogonadotropic hypogonadism 3 with or without anosmia, Prokineticin receptor 2's understanding could pave the way for novel therapeutic strategies. Its involvement in gonadotropin-releasing hormone deficiency highlights its potential in treating reproductive and non-reproductive phenotypes, including anosmia and sensorineural hearing loss.